Sensyne Health Share Discussion Threads

[edwardt] 17/6/2021 15:52

it pains me how much that outfit made when everyone knew they would flip everything. the acd should also take some of the blame.

[rambutan2] 17/6/2021 15:48

Now that is great news!

Noticed in latest Amati fact sheet that they said they'd added a few in May. Will be interesting to see whether any new disclosable holders appear.

So, in theory, the share price should start to head up before long.

[billy3] 15/6/2021 14:47

I mentioned the broker price target a couple of weeks ago.

I read an article yesterday that Wimbledon will be running at full capacity for the final after starting at 50%. Wibledon will be also open for 45k people at half capacity.

These two events and also the F1 will be part of the governments continuing trials to test people back in to large scale events. Of course, each person will be using Excalibur LFT encorporating Sens Magnifye. There should be some nice royalties coming in on this deal as it continues.

It would be nice to see some more figures on its usage.

[edwardt] 11/6/2021 13:26

fear not rambutan. i have worked out overly thinking when it comes to markets is dangerous. luckily my IQ is so low you have to dig to find it.

[bwana mkubwa] 11/6/2021 09:58

I see that Broker Liberum has a price target of 310p, which is more than 100% higher than the current share price, just bought some more

[rambutan2] 10/6/2021 21:22

edwardt, absolutely, but we all know that mr mkt reacts before it thinks things through. And some participants never even get to the thinking stage.

[edwardt] 10/6/2021 21:11

My bet is sensyne has done the data sharing the right way and the fiasco on the wider nhs data proves it is the only way to do it.

[rambutan2] 09/6/2021 22:00

Has been drifting down on low volume this month.
Prob the NHS data kerfuffle hasn't helped sentiment.
Still, a bit odd given the flow of good news recently.
If I wasn't so overweight already I certainly be considering adding.

[volsung] 09/6/2021 10:22

Bought a few more at 145p although the chart isn’t looking great

[zulu_principle] 09/6/2021 09:57

Stop-lossed out (sorry all). Sitting on the cash, hoping to reinvest on further positive news.

[billy3] 01/6/2021 21:00

Good item.

When they said it was called test
To go for the snooker testing I was
Googling it but nothing came up except the Excalibur trial.

It is fantastic that the end to end process had been trialled, approved and adopted by DHSC.

The user just needs the app and the scanned result is uploaded to DHSC.

As I’ve been saying for weeks now....the potential is huge as there is nothing else like it out there.

Pleased that DHSC recognise that too.

[billy3] 01/6/2021 16:47

Yes the government are using Excalibur.
Government paid Sens for the latest pilot then have a license to them for Magnifeye.
It was used as part of the tests getting people back in to events.
The world snooker was an example I’m aware of which was in the press and on Excalibur’s website.

Following on from the above, DHSC have clearly realised how good the product it and has resulted in today’s RNS as it gets rolled out in other areas and sectors.

Now, if I could work out where this was going and here we are today with an initial adoption by DHSC then the only question I have is where are the buyers ?


We have had an announcement that income will exceed and is on target for full year.
Then we have this additional news.
Even if acacia are still unloading which is no doubt what they always intended to do and take profit, then where are the buyers ?

Long term this company is a no brainier.
Peel Hunt rated this again last week as a buy.
I think their target was 310p.

This needs a push back about 180p.

[mcrudden] 01/6/2021 09:40

Yes looks that way, read back to the rns earlier in the year. Exclusive partnership

[davemac3] 01/6/2021 09:31

are the government using Excalibur's LFT?

[billy3] 01/6/2021 09:22

They needed a test to piggy back it off I guess.
Otherwise they would have to license to every company.

Excalibur was already an approved test and has good capacity.

Clearly some impatient people out there and selling at a time when as was said above......the concept of Sens is now a reality.

[davemac3] 01/6/2021 09:00

Why did they make this exclusive to Excalibur?

[billy3] 01/6/2021 08:01

WoooooooooHoooooo :-)

‘Significant commercial’ and ‘national̵7;

Read back everything said before and this was where it was heading.
Adopted by the DHSC and the ONLY product of its type.




Sensyne Health PLC MagnifEye Production Contract with UK DHSC

01/06/2021 7:00am
UK Regulatory (RNS & others)

Sensyne Health (LSE:SENS)
Intraday Stock Chart

Tuesday 1 June 2021
Click Here for more Sensyne Health Charts.
TIDMSENS

RNS Number : 3067A

Sensyne Health PLC

01 June 2021

MagnifEye Production Contract with the UK's Department of Health & Social Care

Oxford, U.K. 01 June 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI technology company, today announces it has signed a production contract with the UK's Department of Health & Social Care (DHSC) to use Sensyne's MagnifEye AI technology for reading COVID-19 lateral flow diagnostic tests as part of the UK government's asymptomatic testing programme.

The scope of this contract with DHSC is for a phased national roll-out over a three-month period in care homes, GP practices and selected private sector organisations with large workforces. Revenues will be shared with Excalibur Health Systems under the terms of the exclusive agreement between the two companies.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said:

"This is a significant commercial milestone in Sensyne's development and underlines the potential of our world-class expertise in clinical AI applied to diagnostic testing. We are delighted to be working with the Department of Health & Social Care to support the UK's national COVID testing programme, which is making a huge impact in helping the nation to recover from the pandemic."

[rambutan2] 28/5/2021 16:14

Courtesy of c itywire today:

Sensyne Health (SENS), which develops medical artificial intelligence products, is on track for a ‘major inflection’ in 2022, says Liberum.

Analyst Graham Doyle reiterated his ‘buy’ recommendation and target price of 310p on the stock, which closed up 1%, or 1.5p, at 156p on Thursday after releasing a trading update. Revenues of £9m plus were better than Liberum’s forecast.

‘Importantly, on the back of a good start to the year with pharma contract momentum, management provided a positive outlook confirming its confidence in hitting consensus expectations which implies a trebling of revenues to £28m,’ he said.

‘Lastly, after doubling its patient dataset over the past week to 18m, management is now ambitiously targeting 100m patients by the end of 2024.’

Doyle said Sensyne had moved from ‘concept to reality’ and was now ‘beginning to generate material revenues with profitability expected in 2023’, meaning there is ‘a lot more to go for’ in the share price.

[billy3] 27/5/2021 07:40

Great update. Plenty of progress and revenue at last.

Let’s see where the share price goes and hopefully some good press coverage.
...................................................................

Sensyne Health PLC Trading Update

27/05/2021 7:00am
UK Regulatory (RNS & others)

Sensyne Health (LSE:SENS)
Intraday Stock Chart

Thursday 27 May 2021
Click Here for more Sensyne Health Charts.
TIDMSENS

RNS Number : 0094A

Sensyne Health PLC

27 May 2021

Sensyne Health Trading Update

FY2021 trading performance ahead of market expectations

Real world patient database and revenues rapidly growing

Sensyne poised for accelerated international growth

Oxford, U.K. 27 May 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company"), the Clinical AI company, today announces an update on trading for the financial year ended 30 April 2021 ("FY 2021"), and an outlook statement.

UPDATE ON TRADING

-- Robust financial performance: FY 2021 unaudited revenues of at least GBP9.0 million (FY 2020: GBP2.1 million audited).

-- Strong revenue growth driven by contracts with life sciences companies, with recognition of the majority of the GBP4.8 million minimum revenues from MagnifEye AI technology contract with Excalibur Health Services ("Excalibur").

-- Cash and cash equivalents were GBP23.6 million (unaudited) and excludes receipt of majority of minimum revenue payments from the Excalibur contract (FY 2020: GBP31.7 million audited).

-- Fast growth of real world patient database: Acceleration in the growth of Sensyne's de-identified and anonymised real world patient database with access to total of 18.2 million unique records from the UK and the US.

-- Access to c.8.5 million patient records in the UK, a three-fold increase during the financial year, following the signing of six new strategic research agreements ("SRAs") with NHS Trusts; provides coverage of c.13% of the UK population and a significant step towards the target of c.20%.

-- In May 2021, the Company signed its first two US SRAs with leading healthcare providers St Luke's University Health Network, serving Pennsylvania and New Jersey, and Colorado Center for Personalised Medicine, providing access to 9.8 million patient records in the US.

-- Sensyne now has one of the world's fastest growing longitudinal patient datasets, that includes the detailed phenotypic and genomic data needed for life sciences research.

-- Life Science commercial agreements: Momentum continues in discovery sciences with new agreements announced with Alexion and Bristol Myers Squibb, and agreement signed with Excalibur Health for AI based diagnostics. Significant opportunity and good traction seen within business development pipeline including ongoing discussions with existing and new clients across the global pharmaceutical and diagnostic industries.

-- Phesi collaboration: First commercial agreement as part of strategic collaboration with Phesi Inc., a clinical data specialist, signed with leading pharmaceutical company in May 2021. Additional commercial agreements for clinical trial optimisation expected during the current financial year.

-- SENSIGHT Platform: Development of SENSIGHT platform to support rapid interrogation of the real world patient database and industrialisation of our offering to life science companies is on track for launch by mid-2021.

-- Diagnostics: Development and launch of MagnifEye (TM) , an AI diagnostic lateral flow test reader during the year. Exclusive licensing and collaboration agreement for lateral flow testing applications secured with Excalibur generating minimum revenues of GBP4.8 million. Additional commercial opportunities for MagnifEye being pursued in the UK and internationally.

-- SENSE Platform: Development of the SENSE healthcare platform building a suite of advanced AI enabled tools for use by healthcare systems and the life science industry. Access to recently expanded real world patient datasets and specialist datasets expected to broaden this portfolio of AI enabled software tools.

-- Regulatory milestones: . UK MHRA emergency use derogation for MagnifEye received in May 2021. SYNE-COV clinical algorithm for assessing risk for COVID-19 patients admitted to hospital achieved UKCA status in February 2021 and submission to the US Food and Drug Administration of SYNE-GDm in May 2021. SYNE-GDm was submitted for approval under the Medical Device Regulation in August 2020 and a decision is expected soon.

-- GDm-Health solution : Patient remote monitoring software for gestational diabetes now used by 56 NHS Trusts helped care for 28,338 pregnancies since launch in the UK. US launch of GDm in partnership with Cognizant in December 2020; uptake has been slower than expected due to impact of Covid-19 pandemic on US healthcare systems and competitive market environment. Other partnership opportunities being explored to support uptake of this software solution in the US market.

Accelerating patient data strategy

With the signing of two US SRAs recently building on our rapidly growing UK datasets, Sensyne Health is now accelerating its strategy to be a global leader in clinical AI with one of the largest and fastest-growing sets of ethical, de-identified and anonymised real world patient data. Sensyne now has access to a total of 18.2 million unique records from in UK and the US.

Sensyne intends to continue to scale its dataset in a highly strategic manner to enhance its provision of high-quality longitudinal health data within the highest quality ethical framework exclusively focused on delivering improved patient care and accelerating medical research. New health care partners are expected to bring geographically diverse data in key therapeutic areas including cardiovascular, oncology and rare diseases. Different data types, including additional deep phenotypic, imaging and genomic data are expected to further enrich the database. In line with its previously announced strategy, Sensyne's focus will be on adding to its strong relationships in the UK and US, followed by expansion into Europe and Asia Pacific to support demand from existing and potential new life sciences customers.

The Company currently has a pipeline of growing SRA opportunities under active discussion with healthcare systems to access a further c.40 million unique patient records in the UK and US alone reinforcing that Sensyne is seen as a partner of choice for healthcare systems. As the recent US agreements show, international SRAs are structured to place a greater emphasis on the future royalty opportunity rather than other economic parameters and allow Sensyne to continue to scale its access to global health data sustainably.

Sensyne seeks to become a leader in the field by building an ethically-sourced real world dataset of c.100 million patient records by the end of 2024, representative of the patient populations in the key markets of interest to the life sciences industry.

OUTLOOK

Sensyne's robust financial performance, continued momentum with life sciences and the scale of the opportunities presented to it provides confidence in the future performance of the Company. Sensyne's rapidly growing patient databases and world-class expertise in clinical AI provide the foundation for substantial revenue growth and the potential to achieve global scale.

The Company anticipates this revenue growth to be driven by life sciences in the near term, taking a flexible approach to the overall mix and to perform in line with its expectations for FY2022 total revenue.

The Company continues to explore strategic opportunities, including acquisitions, that can leverage this strong organic growth and create additional shareholder value.

Lord (Paul) Drayson PhD FREng, Chief Executive Officer of Sensyne Health , commented: "Covid-19 has accelerated the demand for deeply curated real world patient data and AI analytical tools to inform effective decision making in the delivery of patient care and the efficient development of new medicines. Sensyne Health's partnership model for the ethical use of patient data, in partnership with the NHS and US healthcare providers, has enabled it to build a leadership position in clinical AI that is reflected in our robust growth in data and revenues. The Company is now well placed to capitalise on this growth to become the global leader in the ethical application of clinical AI to patient data."

[davemac3] 27/5/2021 07:28

Nice update

[rambutan2] 25/5/2021 16:59

Well, they got 153.5p for them this time...